scholarly article | Q13442814 |
P50 | author | Ke Xu | Q46184469 |
Cynthia T McMurray | Q88307093 | ||
P2093 | author name string | Amy Holt | |
Enrico Gratton | |||
Jerry Vockley | |||
Michael J Bennett | |||
Do Yup Lee | |||
Aris A Polyzos | |||
Helen Budworth | |||
Rupsa Datta | |||
Meghan Hauser | |||
Ken Frankel | |||
Stephanie Mihalik | |||
Kelly Trego | |||
Pike Goldschmidt | |||
P2860 | cites work | NIH Image to ImageJ: 25 years of image analysis | Q23319322 |
Cytoscape: a software environment for integrated models of biomolecular interaction networks | Q24515682 | ||
Fluorescence lifetime imaging of free and protein-bound NADH | Q24563134 | ||
Three-dimensional super-resolution imaging by stochastic optical reconstruction microscopy | Q24642820 | ||
Assembly of endocytic machinery around individual influenza viruses during viral entry | Q24669815 | ||
Genome-wide atlas of gene expression in the adult mouse brain | Q26253934 | ||
Why does brain metabolism not favor burning of fatty acids to provide energy? Reflections on disadvantages of the use of free fatty acids as fuel for brain | Q26825140 | ||
MZmine 2: modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data | Q27136473 | ||
The volatile compound BinBase mass spectral database | Q27807490 | ||
Sub-diffraction-limit imaging by stochastic optical reconstruction microscopy (STORM) | Q27860490 | ||
The chicken or the egg: mitochondrial dysfunction as a cause or consequence of toxicity in Huntington's disease | Q28072937 | ||
Mitochondrial Biology and Neurological Diseases | Q28076942 | ||
Increased susceptibility of striatal mitochondria to calcium-induced permeability transition | Q28183063 | ||
Adipose fatty acid oxidation is required for thermogenesis and potentiates oxidative stress-induced inflammation | Q28255284 | ||
HdhQ111 Mice Exhibit Tissue Specific Metabolite Profiles that Include Striatal Lipid Accumulation | Q28386493 | ||
Mitochondrial targeting of XJB-5-131 attenuates or improves pathophysiology in HdhQ150 animals with well-developed disease phenotypes | Q28386769 | ||
Enhanced neuronal glucose transporter expression reveals metabolic choice in a HD Drosophila model | Q28389710 | ||
Neurological abnormalities in a knock-in mouse model of Huntington's disease | Q28508179 | ||
Age-dependent changes in the calcium sensitivity of striatal mitochondria in mouse models of Huntington's Disease | Q28512442 | ||
Distinct pools of non-glycolytic substrates differentiate brain regions and prime region-specific responses of mitochondria | Q28534698 | ||
Deletion of the huntingtin polyglutamine stretch enhances neuronal autophagy and longevity in mice. | Q30437121 | ||
Hydroethidine- and MitoSOX-derived red fluorescence is not a reliable indicator of intracellular superoxide formation: another inconvenient truth | Q30457642 | ||
Heterogeneity in 1H-MRS profiles of presymptomatic and early manifest Huntington's disease | Q30979352 | ||
Energy defects in Huntington's disease: Why "in vivo" evidence matters. | Q31131432 | ||
Differential loss of striatal projection neurons in Huntington disease | Q33637273 | ||
Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in Huntington's disease model mice | Q33781761 | ||
Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release | Q33913079 | ||
Detection and characterization of the product of hydroethidine and intracellular superoxide by HPLC and limitations of fluorescence | Q33937018 | ||
Impaired brain energy metabolism in the BACHD mouse model of Huntington's disease: critical role of astrocyte-neuron interactions | Q34153434 | ||
Etomoxir mediates differential metabolic channeling of fatty acid and glycerol precursors into cardiolipin in H9c2 cells | Q34176172 | ||
MetaMapp: mapping and visualizing metabolomic data by integrating information from biochemical pathways and chemical and mass spectral similarity | Q34271370 | ||
Targeting of XJB-5-131 to mitochondria suppresses oxidative DNA damage and motor decline in a mouse model of Huntington's disease | Q34309756 | ||
Actin, spectrin, and associated proteins form a periodic cytoskeletal structure in axons | Q34317568 | ||
Creatine supplementation lowers brain glutamate levels in Huntington's disease | Q45239341 | ||
Increased glucose metabolism and ATP level in brain tissue of Huntington's disease transgenic mice | Q45290567 | ||
Striatal hypometabolism in premanifest and manifest Huntington's disease patients | Q45295893 | ||
Neuropathological classification of Huntington's disease | Q45297167 | ||
Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. | Q45299986 | ||
Proton magnetic resonance spectroscopy of cerebrospinal fluid in neurodegenerative disease: indication of glial energy impairment in Huntington chorea, but not Parkinson disease | Q45300611 | ||
Mechanisms underlying neurodegeneration in Huntington disease: applications to novel disease-modifying therapies | Q45304435 | ||
Mitochondrial dysfunction in Huntington's disease: the bioenergetics of isolated and in situ mitochondria from transgenic mice | Q45304684 | ||
The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC/C-Cdh1. | Q45735127 | ||
Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells | Q49145391 | ||
MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis. | Q55518708 | ||
Threshold effect and tissue specificity. Implication for mitochondrial cytopathies | Q73176064 | ||
Glial lipid droplets and ROS induced by mitochondrial defects promote neurodegeneration | Q34458474 | ||
Early deficits in glycolysis are specific to striatal neurons from a rat model of huntington disease | Q35058593 | ||
Extending biochemical databases by metabolomic surveys | Q35084955 | ||
Disruption of astrocyte-neuron cholesterol cross talk affects neuronal function in Huntington's disease. | Q35167605 | ||
Fluorescence lifetime imaging of endogenous biomarker of oxidative stress | Q35627204 | ||
Oxidative metabolism in YAC128 mouse model of Huntington's disease | Q35924062 | ||
Metabolomics by Gas Chromatography-Mass Spectrometry: Combined Targeted and Untargeted Profiling | Q35977700 | ||
Impaired GAPDH-induced mitophagy contributes to the pathology of Huntington's disease | Q36159463 | ||
The phasor approach to fluorescence lifetime imaging analysis | Q36303232 | ||
Phasor fluorescence lifetime microscopy of free and protein-bound NADH reveals neural stem cell differentiation potential | Q36373782 | ||
A Metabolic Study of Huntington's Disease | Q36445216 | ||
Metabolic disruption identified in the Huntington's disease transgenic sheep model | Q36569413 | ||
Dysfunctional Calcium and Glutamate Signaling in Striatal Astrocytes from Huntington's Disease Model Mice | Q36718633 | ||
Beyond the redox imbalance: Oxidative stress contributes to an impaired GLUT3 modulation in Huntington's disease | Q36824396 | ||
Overexpression of glucose-6-phosphate dehydrogenase extends the life span of Drosophila melanogaster | Q36973677 | ||
A role of mitochondrial complex II defects in genetic models of Huntington's disease expressing N-terminal fragments of mutant huntingtin | Q37153804 | ||
The phasor-FLIM fingerprints reveal shifts from OXPHOS to enhanced glycolysis in Huntington Disease | Q37319246 | ||
Mitochondrial permeability transition pore induces mitochondria injury in Huntington disease. | Q37427280 | ||
Frequency of nuclear mutant huntingtin inclusion formation in neurons and glia is cell-type-specific. | Q37456579 | ||
Oxidative metabolism and Ca2+ handling in isolated brain mitochondria and striatal neurons from R6/2 mice, a model of Huntington's disease | Q37530288 | ||
Glyceraldehyde-3-phosphate Dehydrogenase (GAPDH) Aggregation Causes Mitochondrial Dysfunction during Oxidative Stress-induced Cell Death. | Q37735155 | ||
Energy deficit in Huntington disease: why it matters | Q37834195 | ||
Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation | Q37966074 | ||
Assembly factors of human mitochondrial respiratory chain complexes: physiology and pathophysiology | Q38021398 | ||
Cellular and molecular mechanisms of mitochondrial function | Q38061270 | ||
Mutant Huntingtin and Elusive Defects in Oxidative Metabolism and Mitochondrial Calcium Handling | Q38458943 | ||
The role of mitochondrial disturbances in Alzheimer, Parkinson and Huntington diseases | Q38532744 | ||
Astrocytes: a central element in neurological diseases | Q38670385 | ||
Differential proteomic and genomic profiling of mouse striatal cell model of Huntington's disease and control; probable implications to the disease biology | Q38818625 | ||
The search for true numbers of neurons and glial cells in the human brain: A review of 150 years of cell counting | Q38836341 | ||
Respiration-Deficient Astrocytes Survive As Glycolytic Cells In Vivo. | Q38896993 | ||
Imaging and spectroscopic approaches to probe brain energy metabolism dysregulation in neurodegenerative diseases | Q38918493 | ||
Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. | Q40721588 | ||
Characterisation of carnitine palmitoyltransferases in patients with a carnitine palmitoyltransferase deficiency: implications for diagnosis and therapy | Q41356691 | ||
Bioenergetic analysis of isolated cerebrocortical nerve terminals on a microgram scale: spare respiratory capacity and stochastic mitochondrial failure | Q41494079 | ||
Astrocytes and oligodendrocytes in grey and white matter regions of the brain metabolize fatty acids | Q41542336 | ||
Peroxisomal fatty acid beta-oxidation in HepG2 cells | Q41665569 | ||
Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice | Q44316963 | ||
P4510 | describes a project that uses | ImageJ | Q1659584 |
Cytoscape | Q3699942 | ||
P433 | issue | 6 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | double-strand break repair | Q14818014 |
Huntington's disease | Q190564 | ||
reprogramming | Q402093 | ||
astrocyte | Q502961 | ||
Astrocytes | Q62556224 | ||
P304 | page(s) | 1258-1273.e11 | |
P577 | publication date | 2019-03-28 | |
P1433 | published in | Cell Metabolism | Q1254684 |
P1476 | title | Metabolic Reprogramming in Astrocytes Distinguishes Region-Specific Neuronal Susceptibility in Huntington Mice | |
P478 | volume | 29 |
Q92577532 | Alterations in lipid metabolism of spinal cord linked to amyotrophic lateral sclerosis |
Q97692894 | Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing |
Q92861602 | Cellular Specificity and Inter-cellular Coordination in the Brain Bioenergetic System: Implications for Aging and Neurodegeneration |
Q102379328 | Cross-sectional analysis of plasma and CSF metabolomic markers in Huntington's disease for participants of varying functional disability: a pilot study |
Q89982713 | Determining the bioenergetic capacity for fatty acid oxidation in the mammalian nervous system |
Q96610193 | Explorative study of serum biomarkers of liver failure after liver resection |
Q99549175 | Metabolic Constrains Rule Metastasis Progression |
Q89963834 | Metabolic Regulation of Glial Phenotypes: Implications in Neuron-Glia Interactions and Neurological Disorders |
Q90707611 | Mitochondria-Endoplasmic Reticulum Contacts in Reactive Astrocytes Promote Vascular Remodeling |
Q99407805 | Neuronal metabolic rewiring promotes resilience to neurodegeneration caused by mitochondrial dysfunction |
Q90753145 | Pleiotropic Mitochondria: The Influence of Mitochondria on Neuronal Development and Disease |
Q101237342 | ROS networks: designs, aging, Parkinson's disease and precision therapies |
Q92187419 | Selective Neuronal Death in Neurodegenerative Diseases: The Ongoing Mystery |
Search more.